IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that it has been chosen as a small-to-medium enterprise (SME) partner in the newly established London Medical Imaging & Artificial Intelligence Centre for Value-Based Healthcare. With the official public launch having taken place yesterday (28th February), the center has been established as part of the UK Government’s Industrial Strategy Challenge Fund. Led by King’s College London, the new Center will develop and train sophisticated artificial intelligence (AI) algorithms from NHS medical images and patient data to provide tools for clinicians to speed up and improve diagnosis and care across a number of patient pathways including dementia, heart failure and cancer.
In order to achieve these results, the Center brings together an ambitious consortium including London universities, NHS Trusts, industry partners including global multinationals and UK-based SME’s and the Health Innovation Network.
The Center will have a focus on transformation and value-based healthcare, and how advanced imaging and AI technologies can be used to improve the patient journey. In addition to government funding, the consortia partners have also made significant investments to leverage UK research strengths and clinical knowledge into becoming a leading industrial player in AI and healthcare. IXICO will contribute its expertise in neuroimaging and data analysis and benefit from leveraging the centre’s unique infrastructure and collaborative framework to accelerate development of its innovative AI analytics solutions to support improved decision-making in neuroscience clinical development.
Giulio Cerroni, Chief Executive of IXICO, said: “We are excited to be selected to be part of this flagship UK Government initiative to ensure that UK science is at the forefront of the application and impact of Artificial Intelligence to the future of healthcare. The development and application of artificial intelligence technology will enable IXICO to develop highly valued, innovative solutions to our biopharmaceutical clients in support of their neuroscience clinical development programs. We are looking forward to collaborations with other leaders across this expanding field of research.”